Abstract:The tumor microenvironment (TME) is a critical determinant in the initiation, progression, and treatment outcomes of various cancers. Comprising of cancer‐associated fibroblasts (CAF), immune cells, blood vessels, and signaling molecules, the TME is often likened to the soil supporting the seed (tumor). Among its constituents, tumor‐associated macrophages (TAMs) play a pivotal role, exhibiting a dual nature as both promoters and inhibitors of tumor growth. This review explores the intricate relationship between TAMs and the TME, emphasizing their diverse functions, from phagocytosis and tissue repair to modulating immune responses. The plasticity of TAMs is highlighted, showcasing their ability to adopt either protumorigenic or anti‐tumorigenic phenotypes based on environmental cues. In the context of cancer, TAMs' pro‐tumorigenic activities include promoting angiogenesis, inhibiting immune responses, and fostering metastasis. The manuscript delves into therapeutic strategies targeting TAMs, emphasizing the challenges faced in depleting or inhibiting TAMs due to their multifaceted roles. The focus shifts towards reprogramming TAMs to an anti‐tumorigenic M1‐like phenotype, exploring interventions such as interferons, immune checkpoint inhibitors, and small molecule modulators. Noteworthy advancements include the use of CSF1R inhibitors, CD40 agonists, and CD47 blockade, demonstrating promising results in preclinical and clinical settings. A significant section is dedicated to Chimeric Antigen Receptor (CAR) technology in macrophages (CAR‐M cells). While CAR‐T cells have shown success in hematological malignancies, their efficacy in solid tumors has been limited. CAR‐M cells, engineered to infiltrate solid tumors, are presented as a potential breakthrough, with a focus on their development, challenges, and promising outcomes. The manuscript concludes with the exploration of third‐generation CAR‐M technology, offering insight into in‐vivo reprogramming and nonviral vector approaches. In conclusion, understanding the complex and dynamic role of TAMs in cancer is crucial for developing effective therapeutic strategies. While early‐stage TAM‐targeted therapies show promise, further extensive research and larger clinical trials are warranted to optimize their targeting and improve overall cancer treatment outcomes.

TAM Receptor Inhibition–Implications for Cancer and the Immune System

TAM family kinases as therapeutic targets at the interface of cancer and immunity

TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment

TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy

Targeting of TAMs: can we be more clever than cancer cells?

Tumor-Associated Macrophages in Tumor Immunity (vol <i>11</i>, <i>583084</i>, <i>2020</i>)

The Role of TAMs in the Regulation of Tumor Cell Resistance to Chemotherapy

Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC

Immuno-oncology: are TAM receptors in glioblastoma friends or foes?

Targeting Tumor-Associated Macrophages in Cancer Immunotherapy

In vitro and in vivo characterization of small molecule inhibitors of the anti-inflammatory TAM receptor MerTK

Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer

Roles of Tumor-Associated Macrophages in Tumor Environment and Strategies for Targeting Therapy

Tumor-Associated Macrophage Status in Cancer Treatment

Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing

Targeting Tumor-Associated Macrophages As an Antitumor Strategy.

Tumor‐associated macrophages: A sentinel of innate immune system in tumor microenvironment gone haywire

Interactions between tumor-associated macrophages and regulated cell death: therapeutic implications in immuno-oncology

AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew

Therapeutic Potential of Tumor Associated Macrophages